Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT027 in Advanced Peritoneal Tumors
NCT07004647Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2025
- Primary completion
- Oct 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT027 CAR-T cells in peritoneal neoplasms, sponsored by Ruijin Hospital. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
MT027 CAR-T cells
03
Conditions
peritoneal neoplasms
Beyond the preview
Go deeper on NCT07004647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07004647.